Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06882961 in adults with type 2 diabetes inadequately controlled on metformin or lifestyle
2019-000218-12Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in HbA1c at Week 16. Started Jun 2019; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-000218-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000218-12.